Subgroup Analysis: Differences in Maintenance Dosing For UC and CD
Unable to add items
Add to basket failed.
Add to wishlist failed.
Failed to remove from Wish List.
Adding to library failed
Unable to follow podcast
Unable to unfollow podcast
Subgroup Analysis: Differences in Maintenance Dosing For UC and CD
-
Narrated by:
-
By:
Thank you to Johnson & Johnson for their support on this podcast episode.
In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussion with Amanda Wilhite, PA-C, of Houston Methodist Gastroenterology Associates. The episode explores how healthcare professionals may approach the two FDA-approved subcutaneous guselkumab maintenance dosing options for adults with moderate-to-severe Crohn’s disease and ulcerative colitis: 100 mg every eight weeks or 200 mg every four weeks.
Drawing on data from the Phase 3 GALAXI 2 and 3 Crohn’s disease studies and the QUASAR ulcerative colitis maintenance study, Amy and Amanda discuss how disease severity, inflammatory burden, C-reactive protein levels, endoscopic response, previous advanced-therapy exposure, and individual patient needs may inform maintenance-dosing conversations. They also share real-world perspectives on monitoring treatment response and using the lowest effective recommended dosage to maintain therapeutic response.
For additional IBD education, visit the GHAPP ACE app or digital hub.
